AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21717719 — intervention group
Group type: EXPERIMENTAL
Intervention: Second measurement of sensitivity
Number of subjects: 29
Study 21717719 — intervention group
Group type: EXPERIMENTAL
Intervention: First measurement of specificity
Number of subjects: 29
Study 21717719 — intervention group
Group type: EXPERIMENTAL
Intervention: Second measurement of specificity
Number of subjects: 29
Study 21717719 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement (first measurement)
Number of subjects: 29
Study 21717719 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement (second measurement)
Number of subjects: 29
Study 21717719 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined BI-RADS categories agreement
Number of subjects: 29
Study 21717719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer agreement
Number of subjects: 29
Study 21717719 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis on interpreted mammograms
Number of subjects: 29
Study 21717719 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis on courses taken
Number of subjects: 29
Study 19318865 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF) using volar locking plate (n = 53)
Number of subjects: 130
Study 19318865 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and casting (CAST) (n = 61)
Number of subjects: 130
Study 20071596 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV 300 mg with ritonavir (RTV) 100 mg (ATV300/r, n = 95)
Number of subjects: 200
Study 20071596 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV 400 mg (ATV400; n = 105)
Number of subjects: 200
Study 15642080 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day added to simvastatin 20 mg/day
Number of subjects: 214
Study 15642080 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg/day (doubling the dose of simvastatin)
Number of subjects: 214
Study 12140204 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aldose reductase inhibitor (ONO-2235)
Number of subjects: 21
Study 9973093 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening (PSA measurement and DRE)
Number of subjects: 46193
Study 9973093 — intervention group
Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 46193
Study 7478692 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction of m. quadriceps femoris
Number of subjects: 14
Study 7478692 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic cream
Number of subjects: 14
Study 7478692 — intervention group
Group type: COMPARATOR
Intervention: Control cream
Number of subjects: 14
Study 2137902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (GR 38032F)
Number of subjects: 97
Study 2137902 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 97
Study 7006442 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 35868 (Diprivan) 1-2 mg/kg
Number of subjects: 20
Study 7006442 — intervention group
Group type: COMPARATOR
Intervention: Althesin 0.5 ml/kg
Number of subjects: 20
Study 29716660 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended psychosocial support program based on Acceptance and Commitment Therapy, consisting of 1 face-to-face contact, 6 online guided modules, and 1 telephone contact over 8 weeks.
Number of subjects: 140
Study 29716660 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended psychosocial support program
Number of subjects: 140
Study 29716660 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 140
Study 27460267 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic household activities
Number of subjects: 10
Study 27460267 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual METS (METSactual)
Number of subjects: 10
Study 24415271 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril 30 mg plus HCTZ 12.5 mg
Number of subjects: 361
Study 24415271 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 150 mg plus HCTZ 12.5 mg
Number of subjects: 361
Study 24415271 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril + HCTZ
Number of subjects: 361
Study 24415271 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan + HCTZ
Number of subjects: 361
Study 22764601 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + bloodletting (Xingjian (LR 2), Taichong (LR 3), Zhongfeng (LR 4), Ququan (LR 5) and pricking Dadun (LR 1) for bloodletting)
Number of subjects: 30
Study 22764601 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/d, PO in the morning)
Number of subjects: 30
Study 20484492 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message regarding online registration facility
Number of subjects: 1121
Study 20484492 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter with £5 enclosed
Number of subjects: 1121
Study 20484492 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages containing quotes from participants
Number of subjects: 1121
Study 20484492 — intervention group
Group type: COMPARATOR
Intervention: Standard Txt2stop procedures
Number of subjects: 1121
Study 18305954 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicin supplementation
Number of subjects: 0
Study 18305954 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 15804294 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine concentrations (0.1, 1.0, and 10 mg/ml)
Number of subjects: 60
Study 15804294 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline (negative control)
Number of subjects: 60
Study 15804294 — intervention group
Group type: EXPERIMENTAL
Intervention: 100‐mm visual analog scale and a four‐stepped verbal rating scale
Number of subjects: 60
Study 12483236 — intervention group
Group type: COMPARATOR
Intervention: 0.2% CHX rinses
Number of subjects: 22
Study 12483236 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg CHX tablets
Number of subjects: 22
Study 12483236 — intervention group
Group type: COMPARATOR
Intervention: 30 mg CHX tablets
Number of subjects: 22
Study 12483236 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 22
Study 10726236 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 141
Study 7730247 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump (group 2)
Number of subjects: 24
Study 7730247 — intervention group
Group type: COMPARATOR
Intervention: Roller pump (group 1)
Number of subjects: 24
Study 2077497 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine 0.50 mg/lb
Number of subjects: 60
Study 2077497 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine 1.00 mg/lb
Number of subjects: 60
Study 2077497 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine (highest dose)
Number of subjects: 60
Study 2077497 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine sedation
Number of subjects: 60
Study 2077497 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 7443444 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 0
Study 7443444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31688449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled antagonist group (haloperidol, flupentixol, olanzapine)
Number of subjects: 69
Study 31688449 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation antipsychotics (pooled)
Number of subjects: 69
Study 31688449 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 69
Study 28890299 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol (125/6 mcg BD)
Number of subjects: 232
Study 28890299 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol (200/6 mcg BD)
Number of subjects: 232
Study 27449067 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance exercise (two sets of 15-20 repetition maximum)
Number of subjects: 20
Study 27449067 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-load resistance exercise (three sets of 5-8 repetition maximum)
Number of subjects: 20
Study 24798817 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridges to High School Program/Proyecto Puentes a la Secundaria
Number of subjects: 782
Study 22510586 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA hard contact lens
Number of subjects: 14
Study 22510586 — intervention group
Group type: EXPERIMENTAL
Intervention: RGP contact lens
Number of subjects: 14
Study 22510586 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft silicone hydrogel contact lens
Number of subjects: 14
Study 22510586 — intervention group
Group type: COMPARATOR
Intervention: No contact lens
Number of subjects: 14
Study 20441811 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on educational intervention including a demonstration and return demonstration of correct installation and use of a child passenger restraint
Number of subjects: 111
Study 20441811 — intervention group
Group type: COMPARATOR
Intervention: Standardized education session on the safety and use of child passenger restraints (Control group)
Number of subjects: 111
Study 20441811 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on educational intervention
Number of subjects: 111
Study 17959530 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin administration at 3-4 h postburn (group A)
Number of subjects: 20
Study 17959530 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin administration at 10 h postburn (group B)
Number of subjects: 20
Study 17959530 — intervention group
Group type: COMPARATOR
Intervention: Amikacin administration at 20 h postburn (group C)
Number of subjects: 20
Study 17959530 — intervention group
Group type: COMPARATOR
Intervention: Amikacin administration at 30 h postburn (group D)
Number of subjects: 20
Study 16192549 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 69
Study 16192549 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube
Number of subjects: 69
Study 11585103 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment guided by plasma levels of N-BNP
Number of subjects: 69
Study 11585103 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment based on clinical criteria
Number of subjects: 69
Study 9686773 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg efaroxan, given three times per day
Number of subjects: 14
Study 9686773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8021526 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 35
Study 8021526 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 35
Study 8021526 — intervention group
Group type: COMPARATOR
Intervention: Conventional transthoracic echocardiography (TTE)
Number of subjects: 35
Study 2685934 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management with limited surgical excision and radiotherapy
Number of subjects: 0
Study 2685934 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial Ir‐192 boost dose to the tumor bed immediately following resection
Number of subjects: 0
Study 30451147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean lemonade (ML)
Number of subjects: 50
Study 30451147 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (GT)
Number of subjects: 50
Study 30451147 — intervention group
Group type: COMPARATOR
Intervention: Flavoured water (FW)
Number of subjects: 50
Study 28655351 — intervention group
Group type: EXPERIMENTAL
Intervention: eSAGE
Number of subjects: 66
Study 28655351 — intervention group
Group type: COMPARATOR
Intervention: SAGE
Number of subjects: 66
Study 25956954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular phloroglucinol (80 mg)
Number of subjects: 120
Study 25956954 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (400 mg)
Number of subjects: 120
Study 23517244 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (2 sessions)
Number of subjects: 135
Study 23517244 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 135
Study 21807831 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of COSP and CMHA services
Number of subjects: 139
Study 21807831 — intervention group
Group type: COMPARATOR
Intervention: CMHA-only service
Number of subjects: 139
Study 19523013 — intervention group
Group type: COMPARATOR
Intervention: Lecozotan 0.1, 0.25, 0.5, 1 and 5 mg q12h
Number of subjects: 65
Study 19523013 — intervention group
Group type: COMPARATOR
Intervention: Lecozotan 0.5 mg and 5 mg q12h
Number of subjects: 65
Study 19523013 — intervention group
Group type: COMPARATOR
Intervention: Single-dose lecozotan 2, 5 and 10 mg
Number of subjects: 65
Study 19523013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 16428552 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mouse units of BoNT/A
Number of subjects: 0
Study 16428552 — intervention group
Group type: COMPARATOR
Intervention: Pure saline (control)
Number of subjects: 0
Study 15608803 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance
Number of subjects: 589
Study 15608803 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes (both known and newly diagnosed)
Number of subjects: 589
Study 15608803 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific diabetes rates
Number of subjects: 589
Study 15608803 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific insulin resistance rates
Number of subjects: 589
Study 11763111 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pyridostigmine bromide (PB) every 8 hours for 13 doses
Number of subjects: 67
Study 11763111 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg pyridostigmine bromide (PB) every 8 hours for 13 doses
Number of subjects: 67
Study 11763111 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 67
Study 9750974 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive‐behavior therapy (11 sessions)
Number of subjects: 93
Study 9750974 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 93
Study 7995616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal (D‐Ser6)‐gonadotrophin‐releasing hormone (GnRH) analogue (buserelin) administered at a mean dose of 25 micrograms/kg/day for a mean period of 14 months
Number of subjects: 22
Study 7995616 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 22
Study 2459641 — intervention group
Group type: EXPERIMENTAL
Intervention: Central argon laser panretinal photocoagulation (PRP)
Number of subjects: 50
Study 2459641 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral argon laser panretinal photocoagulation (PRP)
Number of subjects: 50
Study 30921375 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated flight tasks for 2 hours
Number of subjects: 50
Study 30921375 — intervention group
Group type: COMPARATOR
Intervention: Rest for 2 hours
Number of subjects: 50
Study 28456026 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia treated in primary care
Number of subjects: 612
Study 26714491 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Parenting intervention (six additional home visits by a Youth Health Care nurse during the first 18 months after childbirth)
Number of subjects: 0
Study 26714491 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 0
Study 24159562 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (median dose 300 mg)
Number of subjects: 2225
Study 24159562 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline or new-onset abnormal thyroid function
Number of subjects: 2225
Study 24159562 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator therapy
Number of subjects: 2225
Study 24159562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2225
Study 21367849 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cystatin C (CysC)
Number of subjects: 160
Study 21367849 — intervention group
Group type: COMPARATOR
Intervention: Serum creatinine (Cr)
Number of subjects: 160
Study 21367849 — intervention group
Group type: EXPERIMENTAL
Intervention: CysC formula
Number of subjects: 160
Study 21367849 — intervention group
Group type: COMPARATOR
Intervention: Cr formula
Number of subjects: 160
Study 18481710 — intervention group
Group type: EXPERIMENTAL
Intervention: Xingnao Kaiqiao acupuncture (once each day, for 4 weeks) + routine treatment of western medicine
Number of subjects: 234
Study 18481710 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture + routine treatment of western medicine
Number of subjects: 234
Study 17071427 — intervention group
Group type: EXPERIMENTAL
Intervention: Propess
Number of subjects: 100
Study 17071427 — intervention group
Group type: COMPARATOR
Intervention: Prostin
Number of subjects: 100
Study 11967729 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (10-20 mg once daily)
Number of subjects: 5
Study 11967729 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (20-40 mg once daily)
Number of subjects: 5
Study 11967729 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan medoxomil (5-20 mg once daily)
Number of subjects: 5
Study 11967729 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 5
Study 10101728 — intervention group
Group type: EXPERIMENTAL
Intervention: D-fenfluramine (D-FEN) 30 mg PO
Number of subjects: 24
Study 10101728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7775610 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine in patients with no liver disease
Number of subjects: 73
Study 7775610 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine in patients with liver disease
Number of subjects: 73
Study 7775610 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine biotransformation parameters (Cl and t1/2)
Number of subjects: 73
Study 2264175 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) vaginal tablets
Number of subjects: 88
Study 2264175 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 88
Study 758705 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight dextran
Number of subjects: 13
Study 758705 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative fluid therapy (Control)
Number of subjects: 13
Study 6822321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid
Number of subjects: 6
Study 6822321 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acids
Number of subjects: 6
Study 6822321 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 6
Study 31888626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous C1‐INH (50 IU/kg)
Number of subjects: 18
Study 31888626 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 18
Study 31888626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous C1‐INH
Number of subjects: 18
Study 29458749 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ferric carboxymaltose (FCM)
Number of subjects: 32
Study 29458749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26007202 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention combined with lifestyle modifications for 3 months
Number of subjects: 100
Study 26007202 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modifications alone for 3 months
Number of subjects: 100
Study 24563628 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled home-based exercise intervention (strength training 3x/week and 30 minutes brisk walking/day)
Number of subjects: 67
Study 24563628 — intervention group
Group type: COMPARATOR
Intervention: Regular physical activity level (control group)
Number of subjects: 67
Study 24563628 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled home-based exercise intervention
Number of subjects: 67
Study 22810740 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive therapy with pantogam at a mean dose of 1.8 g/daily
Number of subjects: 93
Study 22810740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation therapy with pantogam at a mean dose of 1.2 g/daily
Number of subjects: 93
Study 22810740 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 93
Study 20514963 — intervention group
Group type: EXPERIMENTAL
Intervention: New method group (needle inserted into the skin at an angle of 20° and into the caudal space without redirection, n=35)
Number of subjects: 75
Study 20514963 — intervention group
Group type: COMPARATOR
Intervention: Conventional method group (caudal block performed with conventional needle insertion, n=40)
Number of subjects: 75
Study 20514963 — intervention group
Group type: EXPERIMENTAL
Intervention: New method group
Number of subjects: 75
Study 20514963 — intervention group
Group type: COMPARATOR
Intervention: Conventional method group
Number of subjects: 75
Study 17697863 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA) supplementation via flaxseed oil capsules (increasing ALA to 5% of total energy intake) for 8 weeks.
Number of subjects: 57
Study 17697863 — intervention group
Group type: COMPARATOR
Intervention: Control group instructed not to alter their habitual diet for 8 weeks.
Number of subjects: 57
Study 16224843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative (Iop) group received 0.5 mg/kg pethidine intravenously at the time of fascia closure
Number of subjects: 64
Study 16224843 — intervention group
Group type: COMPARATOR
Intervention: Post-operative (Pop) group received 0.5 mg/kg pethidine intravenously on arrival in the post‐anaesthesia care unit
Number of subjects: 64
Study 12296888 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 70
Study 12296888 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory Resistance-Positive Expiratory Pressure (IR-PEP)
Number of subjects: 70
Study 11107575 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with vascular CNS damage
Number of subjects: 90
Study 11107575 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with left hemisphere damage
Number of subjects: 90